AURINIA PHARMACEUTICALS INC

AUPH represents Aurinia Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing therapies for autoimmune and inflammatory diseases. Its primary product is LUPKYNIS (voclosporin), approved for the treatment of lupus nephritis. The company also explores other indications for voclosporin and has a pipeline of drug candidates. AUPH generates revenue primarily through product sales and has partnerships for international development and distribution.

The recent performance of AUPH stock can be tracked by reviewing its price movements over various time frames, such as the past week, month, or year. Key metrics include the current price, daily percentage change, and 52-week range, which are updated regularly. For the most accurate and up-to-date performance information, please refer to the latest AUPH stock data displayed on this page.

Evaluating AUPH's valuation involves analyzing financial metrics such as price-to-sales (P/S), price-to-earnings (P/E), and enterprise value relative to revenue or EBITDA. Because Aurinia may have unique earnings patterns, comparing these ratios to peers in the biotechnology sector and considering pipeline potential is important. Additionally, discounted cash flow models can estimate intrinsic value based on projected product sales and expenses.

AUPH is listed on the Nasdaq Global Select Market and typically experiences moderate to high trading activity, especially during market hours and around news events. Its average daily volume can fluctuate based on investor interest, company announcements, or broader market conditions. For real-time trading volume and liquidity data, please refer to the latest AUPH stock information on this page.

Investing in AUPH carries risks common to biopharmaceutical companies, including clinical trial failures, regulatory hurdles, and competition from other lupus nephritis treatments. Commercialization risks involve market acceptance of LUPKYNIS, reimbursement challenges, and reliance on partnerships. Financial risks include the need for additional funding, potential dilution, and dependence on a single product for revenue. Intellectual property disputes and changes in healthcare policy could also adversely affect the company.

Key financial metrics for AUPH include revenue growth, gross margin, operating expenses, and net income or loss, which reflect the company's profitability and cost management. Cash burn rate and cash runway are critical for assessing financial sustainability, while research and development spending indicates investment in future growth. Investors should also monitor product-specific sales figures, such as LUPKYNIS revenue, and compare them to guidance or analyst estimates.